Y-Mabs Therapeutics Common Stock

The latest common stock for YMAB is $5K as of June 2025. That compares with $4K in the prior-year period — up 25.0% year over year. Investors often review this figure alongside Y-Mabs Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, YMAB's common stock moved from $4K to $5K — a 25.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Y-Mabs Therapeutics's operating scale or balance-sheet position.

A common stock figure of $5K for YMAB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting YMAB's common stock ($5K), review year-over-year change from $4K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Y-Mabs Therapeutics's common stock against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.